T-cell engaging–therapies have transformed the treatment landscape of relapsed and
refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients …

Introduction This systematic review aims to explore the existing evidence on the cost-
effectiveness of brexu-cel across different international jurisdictions. Methods A systematic …

Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen
receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell …

Introduction Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often
require multiple lines of treatment and have a poor prognosis, particularly after failing …

MCL remains incurable, and patients who relapse post BTK inhibitors have poor outcomes.
BsAbs and CAR T cell therapy are novel strategies to treat patients with R/R MCL. These …

Significant progress in determining the molecular origins and resistance mechanisms of
mantle cell lymphoma (MCL) has improved our understanding of the disease's clinical …

A real-world population of patients with relapsed/refractory mantle cell lymphoma (MCL),
including those with high-risk features, derived benefit from brexucabtagene autoleucel …